Zhou Rongrong, Fei Yanghonghong, Sun Leqi, Guo Jian, Zhou Xiaofei, Zhang Xudong
Department of Aesthetic and Plastic Surgery, PLA 117 Hospital, 14 Lingyin Rd., Hangzhou, 310000, Zhejiang, China.
Aesthetic Plast Surg. 2019 Aug;43(4):1044-1053. doi: 10.1007/s00266-019-01396-4. Epub 2019 May 15.
To establish botulinum toxin-A (BTX-A) rejuvenation as an innovative technique to treat facial sagging with descent of the mid and lower face in Asian females.
Between March 2016 and March 2017, 512 female patients with facial sagging were treated with regional platysma BTX-A injection. Droplet injection into the dermis was performed. Among the patients, 192 were recruited into our retrospective study. Eligible patients were divided into a pre-senile group (28-39 years old) and a senile group (> 40 years old). We analyzed the patient/physician-graded improvement, the mean scores of the 5-point improvement scale, and any reported complications.
The overall degree of both patient- and physician-graded mid-face aesthetic improvement was very high. Improvement ratings reached 97.92% for patients and 94.79% for physicians. Improvement ratings were significantly greater in the pre-senile group compared to the senile group (p < 0.001), suggesting that the pre-senile patients were more satisfied with their improvement. Moreover, the percent of patients who reported as "much improved" was significantly higher than the percent of physicians (p < 0.05), suggesting that patients felt more positively about their aesthetic results than the physicians. No severe side effects were reported.
Our results demonstrated that regional BTX-A injection in the dermis for the purpose of aesthetical platysma rejuvenation is safe and effective in patients with facial sagging with descent of the mid and lower face. Specifically, regional platysma injections of BTX-A (BTX-A rejuvenation) can correct descent of the mid and lower face in Asian females, demonstrating clinical utility of this treatment strategy.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
将A型肉毒毒素(BTX-A)年轻化疗法确立为一种治疗亚洲女性面部中下部下垂导致面部松弛的创新技术。
2016年3月至2017年3月期间,对512例面部松弛的女性患者进行了颈阔肌区域BTX-A注射治疗。采用真皮内点状注射。其中192例患者纳入我们的回顾性研究。符合条件的患者分为早老组(28 - 39岁)和老年组(>40岁)。我们分析了患者/医生分级改善情况、5分制改善量表的平均得分以及任何报告的并发症。
患者和医生分级的面部中部美学改善总体程度都非常高。患者的改善率达到97.92%,医生的改善率达到94.79%。早老组的改善率显著高于老年组(p < 0.001),这表明早老患者对自身改善情况更满意。此外,报告为“改善很多”的患者百分比显著高于医生的百分比(p < 0.05),这表明患者对其美学效果的感受比医生更积极。未报告严重副作用。
我们的结果表明,为实现颈阔肌美学年轻化而进行的真皮内区域BTX-A注射,对于面部中下部下垂导致面部松弛的患者是安全有效的。具体而言,BTX-A的区域颈阔肌注射(BTX-A年轻化疗法)可以纠正亚洲女性面部中下部的下垂,证明了这种治疗策略的临床实用性。
证据等级V:本刊要求作者为每篇文章指定证据等级。有关这些循证医学评级的完整描述,请参阅目录或作者在线指南www.springer.com/00266 。